Keyword: Denali Therapeutics
Jnana’s Joanne Kotz to be CEO; BioCardia brings on new clinical VP for phase 3; and Biomatics recruits biopharma veterans for $300M healthcare fund.
Eli Lilly is dropping a BACE inhibitor that was being tested in combination in Alzheimer's disease.
The agreement covers small molecules designed to treat multiple neurodegenerative and systemic inflammatory diseases.
Denali will acquire the rights to bispecific antibodies targeting the blood-brain barrier that were developed under its collaboration with F-star.
A team of scientists clarified the role of the protein LRRK2 in tuberculosis, suspecting that it behaves similarly in Parkinson's.
Researchers at Washington University School of Medicine have found that targeting the APOE protein helps clear Alzheimer's plaques in mice.
Cleveland Clinic researchers depleted BACE1 to reverse amyloid plaque formation in mice with Alzheimer's disease.
Hard on the heels of a big IPO and a lucrative deal with Takeda, one of Denali’s top execs is leaving the company to join anti-aging startup Alkahest.
Takeda has struck two deals this morning as it looks to make good on its ongoing R&D reorganization.